Table 1.
Characterization of the population in the included studies and type of OCTA software used
| Article | Type of Study | OCTA Software | Type of Diabetes | Duration of Diabetes (years) Mean ± SD | Age (years) Mean ± SD or range |
|---|---|---|---|---|---|
| Al-Sheikh et al. [44] (2016) | Cross-sectional | DRI OCTA Triton (Topcon Corporation) | NR |
Control: NA Patients with DR: NR |
Control: 39 (range 30–58) |
| Patients with DR: 72 (range 54–93) | |||||
| Bhanushali et al. [45] (2016) | Cross-sectional | AngioVue Avanti OCTA system (Optovue, Inc., Fremont, CA, USA) | Type 2 | Control: NA | Control:38.7 ± 1.68 |
| Mild NPDR: 11.0 ± 2.31 | Mild NPDR: 64.3 ± 2.16 | ||||
| Moderate NPDR: 15.8 ± 1.17 | Moderate NPDR: 61.1 ± 0.99 | ||||
| Severe NPDR: 26.7 ± 7.69 | Severe NPDR: 59.6 ± 1.56 | ||||
| PDR: 7.69 ± 6.0 | PDR: 59.1 ± 1.75 | ||||
| Carnevali et al. [46] (2017) | Cross-sectional | AngioPlex CIRRUS HD-OCT model 5000 (Carl Zeiss Meditec, Inc., Dublin, USA) | Type 1 | Control: NA | Control:23 ± 2 (range 18–26) |
| NDR: 11 ± 4 | NDR: 22 ± 2 (range 7–18) | ||||
| Dimitrova et al. [47] (2017) | Cross-sectional | AngioVue RTVue-XR Avanti OCTA (Optovue, Inc., Fremont, CA, USA) | Type 2 | Control: NA | Controls: 65 ± 11.35 |
| NDR: 7.37 ± 5.96 | NDR: 69 ± 9.01 | ||||
| Lee et al. [48] (2016) | Cross-sectional | Cirrus Angioplex (Carl Zeiss Meditec, Dublin, CA) | Type 2 | Control: NA | Control: 57.4 ± 11.2 |
| NDR: 9.6 ± 5.4 | NDR: 58.5 ± 12.1 | ||||
| Mild NPDR: 15.8 ± 11.0 | Mild NPDR: 63.7 ± 8.5 | ||||
| Moderate to severe NPDR: 11.6 ± 8.8 | Moderate to severe NPDR: 62.1 ± 7.4 | ||||
| PDR: 20.6 ± 14.6 | PDR: 59.5 ± 7.1 | ||||
| Nesper et al. [49] (2017) | Cross-sectional | AngioVue RTVue-XR Avanti OCTA (Optovue, Inc., Fremont, CA, USA) | Type 1 and 2 | Control: NA | Control: 50 ± 18 |
| NDR: 11 ± 15 | NDR: 57 ± 10 | ||||
| NPDR: 17 ± 12 | NPDR: 54 ± 12 | ||||
| PDR: 19 ± 10 | PDR: 49 ± 14 | ||||
| Simonett et al. [50] (2017) | Cross-sectional |
AngioVue RTVue-XR Avanti OCTA (Optovue, Inc., Fremont, CA, USA) |
Type 1 | Control: NA | Control: 39.6 ± 10.1 |
| Diabetic patients: 21.3 ± 10.6 | Diabetic patients: 42.3 ± 8.6 | ||||
|
Alam et al. [51] (2018) |
Cross-sectional | AngioVue RTVue-XR Avanti OCTA (Optovue, Inc., Fremont, CA, USA) | Type 2 | Control: NA | Control:42 ± 9.8 |
| Mild NPDR: 19.64 ± 13.27 | Mild NPDR: 50.1 ± 12.61 | ||||
| Moderate NPDR: 16.13 ± 10.58 | Moderate NPDR: 50.8 ± 8.39 | ||||
| Severe NPDR: 23.40 ± 11.95 | Severe NPDR: 57.84 ± 10.37 | ||||
| Cao et al. [52] (2018) | Cross-sectional | AngioVue RTVue-XR Avanti OCTA (Optovue, Inc., Fremont, CA, USA) | Type 2 | Control: NA | Control:53.7 ± 9.4 |
| NDR: 6.6 ± 1.9 | NDR: 57.4 ± 13.5 | ||||
| Ciloglu et al. [53] (2019) | Cross-sectional | AngioVue RTVue-XR Avanti OCTA (Optovue, Inc., Fremont, CA, USA) | Type 2 | Control: NA | Control:54.09 ± 1.49 |
| NDR: 13.65 ± 0.66 | NDR: 56.61 ± 1.33 |
DR Diabetic Retinopathy, NA not applicable, NDR No Diabetic Retinopathy, NPDR Nonproliferative Diabetic Retinopathy, NR not reported, OCTA Optical Coherence Tomography Angiography, PDR Proliferative Diabetic Retinopathy, SD Standard Deviation